AExcellent

Boston Scientific Corporation(BSX)

A

Financial data as of Dec 31, 2025Declining · Healthcare

FCF Margin15.5%Free Cash Flow / Revenue
Cash Conversion156.5%Operating CF / Net Income
Free Cash Flow$3.4B
Revenue$20.1B
Net Cash-$9.5BNet debt position
Debt / FCF3.7xElevated debt burden
Current Ratio1.62Adequate short-term liquidity
YoY FCF Growth-20.7%5 of 5 quarters positive

How This Grade Was Calculated

Base grade from FCF margin, adjusted by financial health factors

BaseA
+0.5Healthy FCF margin with manageable debt (15.5%, 3.7x)
-0.5FCF trend declining (-20.7% YoY)
+0.25Solid revenue growth (15.9% YoY)
FinalA

Analysis Summary

Strengths

  • Strong FCF margin (15.5%)
  • Excellent cash conversion (156%)

Concerns

  • Net debt position ($9.5B) — 3.7x FCF, manageable
  • Significant YoY FCF decline (-20.7%)

Financial Breakdown

Key financials compared side by side

Margin Composition

FCF Margin15.5%
Net Margin14.4%
Operating CF Margin22.6%
CapEx Ratio5.6%

Balance Sheet Health

Debt, liquidity, and leverage snapshot

Net Cash-$9.5BNet debt position
Debt / FCF3.7xElevated debt burden
Current Ratio1.62Strong liquidity
Debt / Equity0.47Low leverage

Quarterly FCF Trend

-20.7% YoYDeclining (-20.7%)

Free cash flow per quarter

Sector Comparison — Healthcare

FCF Margin ranked against sector peers

View all →

Detailed Metrics

Company NameBoston Scientific Corporation
SectorHealthcare
Free Cash Flow$3.4B
Revenue$20.1B
Net Income$2.9B
Operating Cash Flow$4.5B
Capital Expenditure$1.1B
FCF Margin15.5%
Cash Conversion Rate156.5%
Net Margin14.4%
Total Debt$11.4B
Total Cash$2.0B
Net Cash-$9.5B
Current Ratio1.62
Debt / Equity0.47
Debt / FCF3.7x
YoY FCF Growth-20.7%
Positive Quarters5 of 5
Trend DirectionDeclining
Report DateDec 31, 2025
GradeA
Data SourceYahoo Finance